<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02395913</url>
  </required_header>
  <id_info>
    <org_study_id>HT-002-02</org_study_id>
    <nct_id>NCT02395913</nct_id>
  </id_info>
  <brief_title>Compare Safety and Pharmacokinetic Properties of Surfolase Capsule(Acebrophylline 100mg) and Surfolase CR(200mg)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hyundai Pharmaceutical Co., LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hyundai Pharmaceutical Co., LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acebrophylline is metabolized by being separated into Ambroxol and 7-theophylline when orally&#xD;
      administered as a salt composed of an acid-base as a compound that was synthesized by and&#xD;
      chloride (salifying) the ambroxol to 7-theophylline. Acebrophylline is selectively applied to&#xD;
      the bronchial or lung tissue and inhibit the activity of phospholipase bronchoalveolar shows&#xD;
      the expectorant action to raise the surface activity of the alveolar, leukotrienes (LTs) and&#xD;
      by suppressing the production of prostaglandins (PGs), showed potent anti-inflammatory&#xD;
      activity, bronchial was celebrated by reducing the bronchial hyperreactivity to normal state&#xD;
      is allowed to recuperate or extended.&#xD;
&#xD;
      It was developed to improve compliance improve pharmaceutically Surfolase&#xD;
      capsule(Acebrophylline 100mg) that intake twice daily 100mg to Surfolase CR(Acebrophylline&#xD;
      200mg) that intake once daily 200mg&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCt of ambroxol</measure>
    <time_frame>blood serum sampling</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of ambroxol</measure>
    <time_frame>blood serum sampling</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf of ambroxol</measure>
    <time_frame>blood serum sampling</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of ambroxol</measure>
    <time_frame>blood serum sampling</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of ambroxol</measure>
    <time_frame>blood serum sampling</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Healthy Male</condition>
  <arm_group>
    <arm_group_label>R</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>T1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>T3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>T4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Surfolase capsule (100mg)</intervention_name>
    <description>Surfolase capsule one capsule twice one days fasting administration</description>
    <arm_group_label>R</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Surfolase CR (200mg, T1)</intervention_name>
    <description>one tablet once one days fasting administration.</description>
    <arm_group_label>T1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Surfolase CR (200mg, T3)</intervention_name>
    <description>one tablet once one days fasting administration.</description>
    <arm_group_label>T3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Surfolase CR (200mg, T4)</intervention_name>
    <description>one tablet once one days fasting administration.</description>
    <arm_group_label>T4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male subjects between the ages of 20 and 55 years, BMI &gt;18.5, &lt;25, inclusive&#xD;
&#xD;
             *Body mass index (kg/m2) = weight(kg)/height(m)2&#xD;
&#xD;
          2. Subject who don't have congenital or chronic diseases and have no abnormal medical&#xD;
             examination results.&#xD;
&#xD;
          3. Subject is healthy (no clinically relevant findings in any of the investigations of&#xD;
             the pre-examination) as judged by the investigator&#xD;
&#xD;
          4. Subjects who signed and dated in informed consent form indicating that the subject has&#xD;
             decided to participate in the study after being informed of all pertinent aspects of&#xD;
             the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject with known for hypersensitivity reaction to acebrophylline, xanthine and food.&#xD;
&#xD;
          2. Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency&#xD;
             or glucose-galactose malabsorption&#xD;
&#xD;
          3. Subject with serious active cardiovascular, respiratory, hepatologic, renal,&#xD;
             hematologic, gastrointestinal, immunologic, dermal, neurologic, or psychological&#xD;
             disease or history of such disease&#xD;
&#xD;
          4. Subject with known for history of gastrointestinal disease or gastrointestinal surgery&#xD;
             which affect on the absorption drug&#xD;
&#xD;
          5. Subjects with any of the following condition in screening (blood pressure, 12-lead&#xD;
             ECG, blood, urinalysis, etc.)&#xD;
&#xD;
          6. Subject with any of the following conditions in laboratory test i. AST(sGOT) or&#xD;
             ALT(sGPT) &gt; Upper normal limit × 1.25 ii. Total bilirubin &gt; Upper normal limit × 1.5&#xD;
&#xD;
          7. If the estimated GFR &lt; 80mL/min/1.76m2 using MDRD formula.&#xD;
&#xD;
          8. Systolic blood pressure &lt;=90mmHg or diastolic blood pressure &gt;=150mmHg or a person&#xD;
             showing the corresponding figures &lt;=50mmHg or &gt;=100mmHg in vital signs.&#xD;
&#xD;
          9. Who has history of drug abuse (especially hypnotic, central acting analgesics,&#xD;
             psychotropic drugs, such as opiates or central nervous system acting drug) or shows&#xD;
             positive reactions to drug of abuse in urine drug screening tests.&#xD;
&#xD;
         10. Excessive caffeine and alcohol intake, smoking person(caffeine: &gt; 5cups/day, alcohol:&#xD;
             &gt;210g/week, tobacco: &gt; 10 cagarettes/day)&#xD;
&#xD;
         11. Use of any prescription medication within 14 days prior to study medication dosing or&#xD;
             use of any medication such as over-the-counter medication including oriental&#xD;
             medication within 7 days prior to study medication dosing&#xD;
&#xD;
         12. Participation in any clinical investigation within 60days prior to study medication&#xD;
             dosing&#xD;
&#xD;
         13. Subjects with whole blood donation within 60days, component blood donation within&#xD;
             30days&#xD;
&#xD;
         14. Subjects with decision of nonparticipation through investigator's review due to&#xD;
             laboratory test results or other excuse such as non-responding to request or&#xD;
             instruction by investigator&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Park</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University Health System, Severance Hospital</affiliation>
  </overall_official>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>February 10, 2015</study_first_submitted>
  <study_first_submitted_qc>March 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2015</study_first_posted>
  <last_update_submitted>March 17, 2015</last_update_submitted>
  <last_update_submitted_qc>March 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

